Camurus AB Total Liabilities
Camurus AB total liabilities. Based on the latest financial reports, Camurus AB (CAMX) has total liabilities worth Skr504.56 Million SEK (≈ $54.30 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CAMX asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Camurus AB (2011–2025)
Total liabilities of Camurus AB from 2011 to 2025. This chart illustrates how Camurus AB's total liabilities have evolved over time, based on quarterly financial data.
Camurus AB Competitors by Total Liabilities
The table below lists competitors of Camurus AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Endeavour Group Ltd
AU:EDV
|
Australia | AU$8.15 Billion |
|
Wix.Com Ltd
NASDAQ:WIX
|
USA | $2.98 Billion |
|
1&1 AG
XETRA:1U1
|
Germany | €2.35 Billion |
|
Seaboard Corporation
NYSE MKT:SEB
|
USA | $3.07 Billion |
|
Suzhou TA&A Ultra Clean Technology Co Ltd
SHE:300390
|
China | CN¥9.52 Billion |
|
SentinelOne Inc
NYSE:S
|
USA | $1.00 Billion |
|
Premier Energies Limited
NSE:PREMIERENE
|
India | Rs65.35 Billion |
|
Franklin Electric Co Inc
NASDAQ:FELE
|
USA | $741.11 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Camurus AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Camurus AB (CAMX) total assets.
Liquidity & Leverage Metrics
Camurus AB Total Liabilities Ratios Explained
Camurus AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 10.15 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Camurus AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Camurus AB (2011–2025)
The table below shows the annual total liabilities of Camurus AB from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr504.56 Million ≈ $54.30 Million |
+7.97% |
| 2024-12-31 | Skr467.33 Million ≈ $50.29 Million |
+12.66% |
| 2023-12-31 | Skr414.82 Million ≈ $44.64 Million |
+33.46% |
| 2022-12-31 | Skr310.82 Million ≈ $33.45 Million |
+33.40% |
| 2021-12-31 | Skr232.99 Million ≈ $25.07 Million |
+18.47% |
| 2020-12-31 | Skr196.66 Million ≈ $21.16 Million |
+40.06% |
| 2019-12-31 | Skr140.41 Million ≈ $15.11 Million |
+24.92% |
| 2018-12-31 | Skr112.40 Million ≈ $12.10 Million |
+23.61% |
| 2017-12-31 | Skr90.93 Million ≈ $9.79 Million |
+20.67% |
| 2016-12-31 | Skr75.36 Million ≈ $8.11 Million |
-57.13% |
| 2015-12-31 | Skr175.79 Million ≈ $18.92 Million |
+108.75% |
| 2014-12-31 | Skr84.21 Million ≈ $9.06 Million |
+36.69% |
| 2013-12-31 | Skr61.61 Million ≈ $6.63 Million |
+258.30% |
| 2012-12-31 | Skr17.20 Million ≈ $1.85 Million |
-77.46% |
| 2011-12-31 | Skr76.30 Million ≈ $8.21 Million |
-- |
About Camurus AB
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029… Read more